Non-invasive molecular imaging metrics to assess disease progression and response to therapy
My interests are Molecular Imaging Probe Development, PET, Radiochemistry, Medicinal Chemistry, Drug Discovery, and HTS. Our lab develops new imaging biomarkers of cancer and other human diseases.
Our multi-disciplinary research program involves the development, validation, and translation of non-invasive molecular imaging metrics to assess disease progression and response to therapy. Projects within our program emphasize molecular imaging of cancer, and notably imaging-based assessment of response to anti-cancer pharmaceuticals in colorectal and breast cancer. We are actively engaged in advancing novel methods to image molecular events in both humans and animal models that include receptor expression, proliferation, angiogenesis, and apoptosis. Among these methods include validation of imaging probes for novel applications, as well as high-throughput small-molecule discovery to develop novel imaging compounds.